Department of Urology, ASST Valle Olona, Ospedale di Busto Arsizio (VA), Busto Arsizio, Italy.
ESUT: European Association of Urology (EAU) Section of Uro-Technology, Novara, Italy.
World J Urol. 2021 Jul;39(7):2375-2382. doi: 10.1007/s00345-020-03468-6. Epub 2020 Sep 30.
To compare intra and perioperative parameters between HoLEP and ThuLEP in the treatment of benign prostatic hyperplasia and to evaluate clinical and functional outcomes of the two procedures with a 12-month follow-up.
A prospective randomized study was performed on 236 consecutive patients who underwent ThuLEP (n = 115), or HoLEP (n = 121) in three different centers. Intra and perioperative parameters were analyzed: operative time, enucleated tissue weight, irrigation volume, blood loss, catheterization time, hospital stay and complications. Patients were evaluated preoperatively and 3 and 12 months postoperatively with the international prostate symptom score (IPSS), the quality of life (QoL) score, post-void residual volume (PVR), PSA and maximum flow rate (Q).
Preoperative variables in each study arm did not show any significant difference. Compared to HoLEP, ThuLEP showed similar operative time (63.69 vs 71.66 min, p = 0.245), enucleated tissue weight (48.84 vs 51.13 g, p = 0.321), catheterization time (1.9 vs 2.0 days, p = 0.450) and hospital stay (2.2 vs 2.8 days, p = 0.216), but resulted in less haemoglobin decrease (0.45 vs 2.77 g/dL, p = 0.005). HoLEP presented a significantly higher number of patients with postoperative acute urinary retention and stress incontinence. No significant differences were found in PSA, Q, PVR, IPSS and QoL score during follow-up.
ThuLEP and HoLEP both relieved lower urinary tract symptoms equally, with high efficacy and safety. ThuLEP detemined reduced blood loss and early postoperative complications. Catheterization time, enucleated tissue, hospital stay, operative time and follow-up parameters did not show any significant difference.
比较经尿道前列腺钬激光剜除术(HoLEP)与经尿道前列腺绿激光汽化切除术(ThuLEP)治疗良性前列腺增生的围手术期参数,并对两种手术方法进行 12 个月随访,评估其临床和功能结局。
对在三个中心接受 ThuLEP(n=115)或 HoLEP(n=121)的 236 例连续患者进行前瞻性随机研究。分析术中及围手术期参数:手术时间、剜除组织重量、灌洗量、出血量、置管时间、住院时间和并发症。患者分别在术前、术后 3 个月和 12 个月时进行国际前列腺症状评分(IPSS)、生活质量评分(QoL)、剩余尿量(PVR)、前列腺特异性抗原(PSA)和最大尿流率(Q)评估。
各研究组的术前变量无显著差异。与 HoLEP 相比,ThuLEP 手术时间相似(63.69 与 71.66 分钟,p=0.245)、剜除组织重量相似(48.84 与 51.13 克,p=0.321)、置管时间相似(1.9 与 2.0 天,p=0.450)和住院时间相似(2.2 与 2.8 天,p=0.216),但血红蛋白下降更少(0.45 与 2.77 克/分升,p=0.005)。HoLEP 术后发生急性尿潴留和压力性尿失禁的患者明显更多。随访期间,PSA、Q、PVR、IPSS 和 QoL 评分无显著差异。
HoLEP 和 ThuLEP 治疗良性前列腺增生的疗效和安全性相当,均可有效缓解下尿路症状。ThuLEP 可减少术中出血量和术后早期并发症。置管时间、剜除组织、住院时间、手术时间和随访参数无显著差异。